Amia Capital LLP Exelixis, Inc. Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$18.39 - $24.8 $284,658 - $383,879	-15,479 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $9,590 - $12,500	-464 Reduced 2.91%	15,479 $378,000
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $144,337 - $240,445	-8,769 Reduced 35.48%	15,943 $378,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $77,852 - $117,371	-5,384 Reduced 17.89%	24,712 $426,000
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $455,954 - $568,513	30,096 New	30,096 $530,000

463

247M

1.7M

1.02M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.27B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.